Milestone reached in Target Discovery Alliance
Since entering a multi-project target discovery collaboration in January 2020, when PhoreMost deployed its phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer Ingelheim, PhoreMost has triggered a milestone payment, achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies to transform patients’ lives. Click to read more...